Tags

Type your tag names separated by a space and hit enter

Ivermectin: A Review in Rosacea.
Am J Clin Dermatol. 2015 Oct; 16(5):447-52.AJ

Abstract

Ivermectin 1% cream (Soolantra(®); Rosiver™; Izefla(®)) is a novel topical agent indicated for the once-daily treatment of inflammatory lesions of rosacea. Ivermectin is a derivative of the avermectin family of macrocyclic lactone parasiticides. It displays anti-inflammatory properties as well as broad-spectrum anti-parasitic activity, both of which may contribute to its efficacy in treating rosacea. In phase III trials of 12 or 16 weeks' duration in adults with moderate to severe papulopustular rosacea, once-daily ivermectin 1% cream improved the symptoms of rosacea (as per Investigator Global Assessment and inflammatory lesion count) and health-related quality of life versus vehicle, and was more effective than twice-daily metronidazole 0.75% cream in terms of these measures. Ivermectin 1% cream continues to provide benefit for up to 52 weeks of treatment, according to extension studies, and is well tolerated, with the most common treatment-related adverse events (skin burning sensation, pruritus, dry skin and skin irritation) each occurring with low incidence (<2%). Thus, ivermectin 1% cream is an effective and well tolerated option for the topical treatment of inflammatory lesions of rosacea, with the convenience of once-daily application.

Authors+Show Affiliations

Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26254001

Citation

Deeks, Emma D.. "Ivermectin: a Review in Rosacea." American Journal of Clinical Dermatology, vol. 16, no. 5, 2015, pp. 447-52.
Deeks ED. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015;16(5):447-52.
Deeks, E. D. (2015). Ivermectin: A Review in Rosacea. American Journal of Clinical Dermatology, 16(5), 447-52. https://doi.org/10.1007/s40257-015-0150-8
Deeks ED. Ivermectin: a Review in Rosacea. Am J Clin Dermatol. 2015;16(5):447-52. PubMed PMID: 26254001.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ivermectin: A Review in Rosacea. A1 - Deeks,Emma D, PY - 2015/8/9/entrez PY - 2015/8/9/pubmed PY - 2016/6/24/medline SP - 447 EP - 52 JF - American journal of clinical dermatology JO - Am J Clin Dermatol VL - 16 IS - 5 N2 - Ivermectin 1% cream (Soolantra(®); Rosiver™; Izefla(®)) is a novel topical agent indicated for the once-daily treatment of inflammatory lesions of rosacea. Ivermectin is a derivative of the avermectin family of macrocyclic lactone parasiticides. It displays anti-inflammatory properties as well as broad-spectrum anti-parasitic activity, both of which may contribute to its efficacy in treating rosacea. In phase III trials of 12 or 16 weeks' duration in adults with moderate to severe papulopustular rosacea, once-daily ivermectin 1% cream improved the symptoms of rosacea (as per Investigator Global Assessment and inflammatory lesion count) and health-related quality of life versus vehicle, and was more effective than twice-daily metronidazole 0.75% cream in terms of these measures. Ivermectin 1% cream continues to provide benefit for up to 52 weeks of treatment, according to extension studies, and is well tolerated, with the most common treatment-related adverse events (skin burning sensation, pruritus, dry skin and skin irritation) each occurring with low incidence (<2%). Thus, ivermectin 1% cream is an effective and well tolerated option for the topical treatment of inflammatory lesions of rosacea, with the convenience of once-daily application. SN - 1179-1888 UR - https://brain.unboundmedicine.com/medline/citation/26254001/Ivermectin:_A_Review_in_Rosacea_ DB - PRIME DP - Unbound Medicine ER -